Hygieia

Hygieia Extends Series B Round to $22 Million with Participation from Strategic Investors

Retrieved on: 
Tuesday, May 2, 2023
FDA, Diabetes, Health Technology, Health Insurance, Insurance, Other Health, Technology, Finance, Practice Management, Pharmaceutical, Professional Services, Medical Devices, Venture Capital, Artificial Intelligence, Biotechnology, Health, Insulin, Medicaid, Endocrinology, Therapy, Type 2 diabetes, Bashan, Medicare, Patient, Risk, Pharmaceutical industry, Hygieia

Hygieia , a digital therapeutics company for insulin therapy, is extending its Series B funding round to $22 million with a lead investment from Firstime Ventures and additional investment from two strategic partners.

Key Points: 
  • Hygieia , a digital therapeutics company for insulin therapy, is extending its Series B funding round to $22 million with a lead investment from Firstime Ventures and additional investment from two strategic partners.
  • Patients get the correct insulin dose at each injection, without the need for physician intervention.
  • Studies have shown that nearly 90 percent of d-Nav patients have improved A1C levels within 90 days*, without increasing the risk for hypoglycemia**.
  • Hygieia is building the nation’s leading network of diabetes care centers driven by the d-Nav Technology.

Hygieia Expands to Arizona, as Endocrinology Associates, PA, Joins d-Nav® Insulin Management Clinical Partnership Program

Retrieved on: 
Tuesday, January 10, 2023
Medical Devices, FDA, Diabetes, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, American Association of Clinical Endocrinologists, Insulin, FDA, MD, Risk, Health, American Diabetes Association, Partnership, Patient, Therapy, Diabetes, Physician, Endocrinology, Medical device, Pharmaceutical industry, Hygieia

Hygieia, a provider of digital therapeutics for insulin management, has added Endocrinology Associates, PA, in Scottsdale and Chandler, AZ, as a clinical partner.

Key Points: 
  • Hygieia, a provider of digital therapeutics for insulin management, has added Endocrinology Associates, PA, in Scottsdale and Chandler, AZ, as a clinical partner.
  • Patients who use insulin for diabetes require time-consuming, ongoing care management to keep their blood sugar levels stable.
  • The unique d-Nav® Insulin Management Program uses FDA-cleared technology to autonomously prescribe the appropriate insulin dose each time a patient prepares to inject.
  • For more information on the d-Nav Insulin Management Program, visit d-nav.com or call 734-369-9980.

Hygieia adds to team, continues rapid, national expansion of its d-Nav® Insulin Management Program

Retrieved on: 
Tuesday, December 13, 2022
Technology, Research, Diabetes, Other Technology, Biotechnology, Health, General Health, Other Science, Science, Therapy, Physician, Insulin, Patient, Research, FDA, RNS, Growth, Lancet, Marketing, American Medical Group Association, National Association Medical Staff Services, Risk, Pharmaceutical industry, Medicine, Medical device, Hygieia

For more information on Hygieia and the d-Nav insulin management technology, visit d-Nav.com or call 734-369-9980.

Key Points: 
  • For more information on Hygieia and the d-Nav insulin management technology, visit d-Nav.com or call 734-369-9980.
  • The d-Nav Insulin Management Program adds clinical support that helps people with type 2 diabetes adjust their insulin doses according to their bodys changing insulin needs.
  • The d-Nav Insulin Management Program has been peer-reviewed with studies published in leading medical journals.
  • Automated insulin dosing guidance to optimise insulin management in patients with type 2 diabetes: a multicentre, randomised controlled trial.

Hygieia adds clinical partners in New York and North Carolina to its d-Nav® Insulin Management Program

Retrieved on: 
Monday, September 12, 2022
Biotechnology, Managed Care, Health, Diabetes, Artificial Intelligence, Data Management, Health Technology, Technology, Therapy, Time, ECNU, Risk, Weight loss, FDA, Lancet, Population, Partnership, Diabetes, Endocrinology, Patient, Program, Insulin, Physician, American Association of Clinical Endocrinologists, Technology, Degenerative disease, FACE, Science, American Diabetes Association, Pharmaceutical industry, Medicine, Medical device, Hygieia

Most physicians do not have the time or resources to analyze and adjust their patients insulin doses as often as needed.

Key Points: 
  • Most physicians do not have the time or resources to analyze and adjust their patients insulin doses as often as needed.
  • With the d-Nav clinical partnership, endocrinologists can ensure their patients receive necessary dose adjustments whenever needed, without an office visit.
  • The unique d-Nav Insulin Management Program uses the only FDA-cleared technology to autonomously prescribe the appropriate insulin dose each time a patient prepares to inject.
  • The d-Nav Insulin Management Program adds clinical support that helps people with type 2 diabetes adjust their insulin doses according to their bodys changing insulin needs.

Hygieia adds Metro Detroit Endocrinology Center as clinical partner for its d-Nav® Insulin Management Program

Retrieved on: 
Tuesday, August 30, 2022
Managed Care, Research, General Health, Pharmaceutical, Arab American, Consumer, Technology, Artificial Intelligence, Science, FDA, Health, Diabetes, Other Science, Partnership, Technology, Program, Endocrinology, Physician, Degenerative disease, American Diabetes Association, Lancet, MD, Insulin, FDA, Therapy, Population, Communication, Risk, Diabetes, Hypoglycemia, Patient, Pharmaceutical industry, Medical device, Medicine, Hygieia

Hygieia, a provider of digital therapeutics for insulin management, has added Metro Detroit Endocrinology Center in Dearborn as a clinical partner.

Key Points: 
  • Hygieia, a provider of digital therapeutics for insulin management, has added Metro Detroit Endocrinology Center in Dearborn as a clinical partner.
  • The unique d-Nav Insulin Management Program uses AI-powered technology to prescribe the appropriate insulin dose each time a patient prepares to inject.
  • Metro Detroit Endocrinology Center, one of the largest endocrinology practices in Michigan, is incorporating the d-Nav program into a standard protocol for its eligible patients.
  • The d-Nav Insulin Management Program adds clinical support that helps people with type 2 diabetes adjust their insulin doses according to their bodys changing insulin needs.

Slone Partners Places Doug Lawrence as Chief Executive Officer at Hygieia

Retrieved on: 
Friday, August 26, 2022
People, University, BD (company), CEO, Technology, Business administration, Master of Business Administration, Precision medicine, Lancet, Type 2 diabetes, MBA, Insulin, Leadership, Biotechnology, FDA, Risk, BSE, Marketing, Patient, Pharmaceutical industry, Management, Engineering, Science, Hygieia

SOUTH RIDING, Va., Aug. 26, 2022 /PRNewswire-PRWeb/ -- Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, has announced the placement of Doug Lawrence as Chief Executive Officer (CEO) at Hygieia, a leading digital therapeutics company for insulin therapy, where he will be responsible for leading operations, development, and global growth of the company and its d-Nav® Insulin Management Program.

Key Points: 
  • An experienced CEO, Lawrence has previously led three companies, including CeQur, a company that produces insulin patch pumps to treat type 2 diabetes.
  • He also led the diabetes division at Becton Dickinson (now Embecta ), a leading manufacturer of insulin syringes and pen needles.
  • "Now, with Doug serving as CEO, we will work together to build the nation's leading network of diabetes clinics.
  • Slone Partners delivers the leaders who build amazing and diverse life sciences and healthcare organizations People Are Our Science.

Diabetes Technology Leader and Global Business Executive Doug Lawrence Joins Hygieia as CEO

Retrieved on: 
Tuesday, August 23, 2022
Medical Supplies, Medical Devices, Health, Diabetes, General Health, Biotechnology, Partnership, BD (company), CEO, Technology, Safety, National Health Service, ...Continued, Type 1 diabetes, National Health Service (England), Physician, Lancet, Multimedia, American Medical Group Association, Type 2 diabetes, Patient, Insulin, Leadership, FDA, Therapy, Risk, Health, Medical device, Pharmaceutical industry, Hygieia

Hygieia, a digital therapeutics company for insulin therapy, has appointed Doug Lawrence its chief executive officer, responsible for leading operations, development, and global growth of the company and its d-Nav Insulin Management Program.

Key Points: 
  • Hygieia, a digital therapeutics company for insulin therapy, has appointed Doug Lawrence its chief executive officer, responsible for leading operations, development, and global growth of the company and its d-Nav Insulin Management Program.
  • Lawrence is an experienced CEO who previously led three companies including CeQur, a company that makes insulin patch pumps to treat type 2 diabetes.
  • Previously, he led the diabetes business at Becton Dickinson (now Embecta), the worlds leading manufacturer of insulin syringes and pen needles.
  • Now, with Doug serving as CEO, we will work together to build the nations leading network of diabetes clinics.

UAT Group Subsidiary Launches New Hygieia Ageless Skin Care Line

Retrieved on: 
Friday, August 12, 2022
Woman, OTC Markets Group, Hygieia, Industry, TDC, GLOBE, UAT, The Unlimited Dream Company, Female, Technology, Ageless, Sale, LLC, UATG, Skin care, THIS, Man, NEWS, Quality of life, Male, Company, Judgement, Skin, Ageing, OTC, CAGR, News, Rejuvenation, Amazon, John Foster Dulles, THE, Cosmetics

FL, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Umbra Applied Technologies Group, Inc. (OTC Pink: UATG) ("UAT Group") announced today that its subsidiary, The Dreaming Company, LLC (TDC), is re-branding and expanding its highly lauded Hygieia Skin care product suite as Hygieia Ageless.

Key Points: 
  • FL, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Umbra Applied Technologies Group, Inc. (OTC Pink: UATG) ("UAT Group") announced today that its subsidiary, The Dreaming Company, LLC (TDC), is re-branding and expanding its highly lauded Hygieia Skin care product suite as Hygieia Ageless.
  • In the coming weeks, Hygiea Ageless will be expanding on its already impressive suite of luxury skin care products with the release of seven new cutting-edge age defying products.
  • The paraben free, Hygieia Ageless product line contains antioxidant properties to strengthen the skins defenses, minimize signs of aging, and nourish the skin.
  • Umbra Applied Technologies Group Chief Executive Officer, Alex Umbra, commented, "The expansion of the Hygieia Ageless line represents a portion of an eco-system that addresses quality of life by extending beyond a complete skin care system.

UAT Group Subsidiary, The Dreaming Company Announces Hygieia Eye Gel

Retrieved on: 
Tuesday, August 2, 2022
Neuromuscular junction, Sale, Skin, Eye, GLOBE, OTC Markets Group, Hygiea, John Foster Dulles, Woman, Fatigue, Judgement, Rejuvenation, Collagen, News, THE, Cell, Inflammation, Skin care, The Unlimited Dream Company, Health, Ageing, Periorbital puffiness, Technology, Puffy, Company, THIS, Darkness, UAT, Hygieia, NEWS, OTC, Airline, Cosmetics

Tampa, FL, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Umbra Applied Technologies Group, Inc. (OTC Pink UATG) ("UAT Group") announced today that its subsidiary, The Dreaming Company, is expanding on its Hygieia product line with the launch of a new premium revitalizing eye gel.

Key Points: 
  • Tampa, FL, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Umbra Applied Technologies Group, Inc. (OTC Pink UATG) ("UAT Group") announced today that its subsidiary, The Dreaming Company, is expanding on its Hygieia product line with the launch of a new premium revitalizing eye gel.
  • The Dreaming Company CEO, Blake Cooley, stated: We engineered our Hygieia Eye Gel to redefine the standard in under eye care for puffy under eyes.
  • Engineered to enhance the skins barrier function and natural collagen production, Hygieia Eye Gel bolsters the skins regenerative properties.
  • The paraben free, Hygieia Eye Gel contains antioxidant properties to strengthen the skins defenses, minimize signs of aging, fatigue and dullness.

UAT Group Subsidiary, The Dreaming Company Announces Hygieia Bedding Line

Retrieved on: 
Tuesday, July 26, 2022
Sale, Time, Skin, GLOBE, OTC Markets Group, TDC, UATG, GSM, Judgement, Health, News, THE, Quality of life, The Unlimited Dream Company, Technology, Breathability, Company, THIS, UAT, Hygieia, Sleep, NEWS, OTC, Airline, Pharmaceutical industry

Tampa, FL, July 26, 2022 (GLOBE NEWSWIRE) -- Umbra Applied Technologies Group, Incs (OTC Pink: UATG) ("UAT Group"), announced today that its subsidiary, The Dreaming Company, is expanding on the Hygieia product line with the launch of a new premium bedding line, Hygieia Sleep.

Key Points: 
  • Tampa, FL, July 26, 2022 (GLOBE NEWSWIRE) -- Umbra Applied Technologies Group, Incs (OTC Pink: UATG) ("UAT Group"), announced today that its subsidiary, The Dreaming Company, is expanding on the Hygieia product line with the launch of a new premium bedding line, Hygieia Sleep.
  • The Dreaming Company CEO, Blake Cooley, stated: We have spent a lot of time and energy helping Americans to expose their inner goddess with our Hygieia Skin brand.
  • For more information about The Dreaming Company, go here: https://thedreamingcompany.com/
    About Umbra Applied Technologies Group, Inc.
  • UAT Group is a holding company with interests in both public and private companies during the early stages of development as well as growth stages of companies with a synergistic business model to UAT Group subsidiaries.